Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c, Raises FY Guidance
November 5, 2019 4:22 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.10, $0.51 better than the analyst estimate of $3.59. Revenue for the quarter came in at $538 million versus the consensus estimate of $524.39 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $15.50-$16.15, versus the consensus of $15.03.... More
